Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

CERTEST BIOTEC

Certest Biotec, S.L. develops and manufactures IVD products in the human clinical testing field, including rapid test... read more Featured Products: More products

Download Mobile App




New Multiplex Assay for Rapid Diagnosis of Atypical Pneumonia

By LabMedica International staff writers
Posted on 21 Sep 2021
CerTest Biotec (Zaragoza, Spain) has developed and validated the CE-IVD multiplex assay VIASURE C. More...
pneumoniae, M. pneumoniae & L. pneumophila real time PCR kit for the detection of principal pathogens implicated in atypical pneumoniae.

One of the most challenging issues in the management of patients with atypical pneumoniae is the rapid identification of the microbial etiology to guide and personalize the initial antimicrobial therapy. A critical factor in the selection of a diagnostic assay for respiratory infections is the time required to obtain the test result. Only those diagnostic tests that provide results within the first 24 hours can actually assist the clinician to guide the initial antimicrobial therapy.

DNA amplification using the polymerase chain reaction (PCR) is a technique with the potential to offer rapid results in the diagnosis of bacterial pneumonia. Multiplex Real-time PCR is highly sensitive technique for the rapid detection of RNA/DNA in clinical specimens. This technique is particularly advantageous for the detection of fastidious or difficult to culture organisms such as these three atypical pathogens. Several conventional PCR assays and multiplex assays have been developed and have demonstrated sensitivity and specificity better than microbiologic tests. However, a small number of these contain the needed CE-IVD marking necessary for use in clinical diagnosis.

CerTest’s CE-IVD multiplex assay VIASURE C. pneumoniae, M. pneumoniae & L. pneumophila real time PCR detection kit has been developed and validated for the detection of the principal pathogens implicated in atypical pneumoniae. The clinical validation demonstrated that the molecular assay is a sensitive, useful, cheap, and above all a rapid diagnostic tool for the management of atypical pneumonia patients. Moreover, the type of respiratory sample is not a limiting factor as the molecular assay accurately detects the pathogens in upper and lower respiratory samples. Additionally, the multiplex strategy offers an obvious and important clinical advantage as it minimizes the risk that the causative search is biased by overlapping clinical presentations of distinct causes. The application of the CE-IVD multiplex assay VIASURE C. pneumoniae, M. pneumoniae & L. pneumophila real time PCR detection kit from CerTest is expected to significantly improve diagnostics for atypical pneumonia-associated bacterial pathogens.

 

Related Links:

CerTest Biotec



New
Gold Member
Collection and Transport System
PurSafe Plus®
Portable Electronic Pipette
Mini 96
New
Hemodynamic System Monitor
OptoMonitor
New
Gold Member
Immunochromatographic Assay
CRYPTO Cassette
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: Over 100 new epigenetic biomarkers may help predict cardiovascular disease risk (Photo courtesy of 123RF)

Routine Blood Draws Could Detect Epigenetic Biomarkers for Predicting Cardiovascular Disease Risk

Cardiovascular disease is a leading cause of death worldwide, yet predicting individual risk remains a persistent challenge. Traditional risk factors, while useful, do not fully capture biological changes... Read more

Hematology

view channel
Image: New research points to protecting blood during radiation therapy (Photo courtesy of 123RF)

Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments

Scientists have long focused on protecting organs near tumors during radiotherapy, but blood — a vital, circulating tissue — has largely been excluded from dose calculations. Each blood cell passing through... Read more

Immunology

view channel
Image: The VENTANA HER2 (4B5) test is now CE-IVDR approved (Photo courtesy of Roche)

Companion Diagnostic Test Identifies HER2-Ultralow Breast Cancer and Biliary Tract Cancer Patients

Breast cancer is the most common cancer in Europe, with more than 564,000 new cases and 145,000 deaths annually. Metastatic breast cancer is rising in younger populations and remains the leading cause... Read more

Pathology

view channel
Image: An adult fibrosarcoma case report has shown the importance of early diagnosis and targeted therapy (Photo courtesy of Sultana and Sailaja/Oncoscience)

Accurate Pathological Analysis Improves Treatment Outcomes for Adult Fibrosarcoma

Adult fibrosarcoma is a rare and highly aggressive malignancy that develops in connective tissue and often affects the limbs, trunk, or head and neck region. Diagnosis is complex because tumors can mimic... Read more

Technology

view channel
Image: Conceptual design of the CORAL capsule for microbial sampling in the small intestine (H. Mohammed et al., Device (2025). DOI: 10.1016/j.device.2025.100904)

Coral-Inspired Capsule Samples Hidden Bacteria from Small Intestine

The gut microbiome has been linked to conditions ranging from immune disorders to mental health, yet conventional stool tests often fail to capture bacterial populations in the small intestine.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.